---
schema_version: "secwatch.filing_event.v1"
accession: "0001447028-24-000061"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2024-05-28T23:59:59+00:00"
generated_at: "2026-06-01T07:57:24.516630+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Arbutus shareholders approve 9.5M share increase under 2016 Omnibus Plan

## Summary
- Amendment increases aggregate authorized shares by 9,500,000 common shares.
- All seven director nominees (Torti, McElhaugh, Burgess, Henriques, Manchester, Meyers, Rewolinski) elected.
- Non-binding advisory vote on named executive officer compensation approved (99.3M for, 13.5M against).
- Ernst & Young LLP appointed as independent auditor for FY 2024.

## SEC filing metadata
- accession: 0001447028-24-000061
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2024-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000144702824000061/0001447028-24-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000144702824000061/abus-20240522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447028-24-000061
- JSON: https://secwatch.observer/filing/0001447028-24-000061.json
- Plain text: https://secwatch.observer/filing/0001447028-24-000061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.